Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response
复制标题
DOI：
10.1016/j.vaccine.2004.07.014
复制
发表时间：
2004-12-16
期刊：
影响因子：
5.5
通讯作者：
Lambert, PH
中科院分区：
文献类型：
--
作者：
Siegrist, CA;Pihlgren, M;Lambert, PH
我们评估了由单独使用明矾吸附的HBsAg或使用含有CpG基序（CpG 7909）的新型佐剂进行人类免疫引起的亲合力成熟过程。平均亲合力指数和低亲合力和高亲合力抗-HBs的分布表明，亲合力操纵基本上发生在启动后较晚。CpG 7909显著增强了这种亲和力成熟过程，增加了高活性抗体的库。CpG 7909的影响是抗原特异性的、同种型特异性的，并且与对抗-HBs产生的影响不同，因为亲合力与抗-HBs IgG滴度不相关。这是首次证明新型人类佐剂可以诱导具有更高抗原结合亲和力的抗体。(C)2004爱思唯尔有限公司保留所有权利。
We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity manturation essentially takes place late after priming. CpG 7909 markedly enhanced this affinity maturation process, increasing the pool of high-activity antibodies. The influence of CpG 7909 was antigen-specific, isotype-specific and distinct from the influence on anti-HBs production, as avidity did not correlate with anti-HBs IgG titers. This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity. (C) 2004 Elsevier Ltd. All rights reserved.